These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
400 related items for PubMed ID: 26578027
1. Idarucizumab: First Global Approval. Burness CB. Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027 [Abstract] [Full Text] [Related]
2. [The first experience with dabigatran antidote in the University Hospital Pilsen]. Šlechtová J, Hajšmanová Z, Lavičková A, Šigutová P. Cas Lek Cesk; 2016 Dec; 155(8):442-444. PubMed ID: 28098476 [Abstract] [Full Text] [Related]
3. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects. Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674 [Abstract] [Full Text] [Related]
4. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Sié P. Drug Des Devel Ther; 2016 Nov; 10():1683-9. PubMed ID: 27274201 [Abstract] [Full Text] [Related]
5. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review. Thibault N, Morrill AM, Willett KC. Am J Ther; 2018 Nov; 25(3):e333-e338. PubMed ID: 27175894 [Abstract] [Full Text] [Related]
6. Idarucizumab: A Review as a Reversal Agent for Dabigatran. Syed YY. Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764 [Abstract] [Full Text] [Related]
7. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote. Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821 [Abstract] [Full Text] [Related]
8. Evidence Supporting Idarucizumab for the Reversal of Dabigatran. Pollack CV. Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285 [Abstract] [Full Text] [Related]
9. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation. Yogaratnam D, Ditch K, Medeiros K, Doyno C, Fong JJ. Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324 [Abstract] [Full Text] [Related]
10. Idarucizumab: The Antidote for Reversal of Dabigatran. Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Circulation; 2015 Dec 22; 132(25):2412-22. PubMed ID: 26700008 [No Abstract] [Full Text] [Related]
11. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence. Giustozzi M, Verso M, Agnelli G, Becattini C. J Thromb Thrombolysis; 2017 Nov 22; 44(4):527-535. PubMed ID: 28913672 [Abstract] [Full Text] [Related]
13. The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran. O'Malley PA. Clin Nurse Spec; 2016 Nov 22; 30(2):81-3; quiz E9. PubMed ID: 26848896 [No Abstract] [Full Text] [Related]
14. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Brennan Y, Favaloro EJ, Pasalic L, Keenan H, Curnow J. Intern Med J; 2019 Jan 22; 49(1):59-65. PubMed ID: 29869387 [Abstract] [Full Text] [Related]